Literature DB >> 19513858

Large mass affecting retroperitoneal great vessels: a rare presentation of a cancer of unknown primary with diagnostic dilemma and challenged surgical intervention.

Paraskevi Stakia1, Panagiotis Lagos, Stavros Gourgiotis, Vasilios D Tzilalis, Stavros Aloizos, Nikolaos S Salemis.   

Abstract

INTRODUCTION: Cancers of unknown primary site (CUPs) consist of a clinical entity which accounts for 3-5% of all solid tumor patients. They are metastatic solid tumors whose fundamental characteristic is the absence of identifiable site of the primary tumor. CASE REPORT: We report the case of a completely asymptomatic 34-year-old man with a palpated huge mass found incidentally in the left abdomen. All the investigations were normal. During the operation, a large mass was identified 2 cm below the left renal artery which was displacing and encompassing the great retroperitoneal vessels and the left ureter. A complete resection of the mass was performed while the histological examination revealed a solitary retroperitoneal lymph node categorized as metastatic adenocarcinoma of unknown primary site.
CONCLUSION: It is essential to assess the high incidence of patients with cancer who present with CUP. Early surgical excision of the metastatic lesion followed by adjuvant combination chemotherapy should be considered for patients with only a single site of malignancy.

Entities:  

Mesh:

Year:  2009        PMID: 19513858     DOI: 10.1007/s12029-009-9076-9

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  12 in total

1.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.

Authors:  A J van de Wouw; M L G Janssen-Heijnen; J W W Coebergh; H F P Hillen
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

2.  Taxane-based chemotherapy for patients with carcinoma of unknown primary site.

Authors:  F A Greco; J Gray; H A Burris; J B Erland; L H Morrissey; J D Hainsworth
Journal:  Cancer J       Date:  2001 May-Jun       Impact factor: 3.360

3.  Cancer of Unknown Primary Origin.

Authors: 
Journal:  Oncologist       Date:  1997

4.  Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.

Authors:  M Saghatchian; K Fizazi; C Borel; M Ducreux; P Ruffié; T Le Chevalier; C Théodore
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

5.  Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.

Authors:  Stéphane Culine; Michel Fabbro; Marc Ychou; Gilles Romieu; Didier Cupissol; Frédéric Pinguet
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

Review 6.  Cancer of unknown primary site: missing primary or missing biology?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Nicholas Pavlidis
Journal:  Oncologist       Date:  2007-04

Review 7.  Metastases of unknown primary site.

Authors:  B C Lembersky; L C Thomas
Journal:  Med Clin North Am       Date:  1996-01       Impact factor: 5.456

Review 8.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

9.  Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002).

Authors:  R Bugat; A Bataillard; T Lesimple; J J Voigt; S Culine; A Lortholary; Y Merrouche; G Ganem; M C Kaminsky; S Negrier; M Perol; C Laforêt; P Bedossa; G Bertrand; J M Coindre; K Fizazi
Journal:  Br J Cancer       Date:  2003-08       Impact factor: 7.640

10.  Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site.

Authors:  A Piga; R Nortilli; G L Cetto; N Cardarelli; S Luzi Fedeli; G Fiorentini; M D'Aprile; F Giorgi; A P Parziale; A Contu; R Montironi; R Gesuita; F Carle; R Cellerino
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.